Evidence map›Paper›PMID 33291471›Full record

ArticleCancers2020

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study.

Mohamed Zaid, Lauren Widmann, Annie Dai, Kevin Sun, Jie Zhang, Jun Zhao, Mark W Hurd, Gauri R Varadhachary, Robert A Wolff, Anirban Maitra and 8 more

Abstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. The impact of radiomics in diagnosis and staging of pancreatic cancer.Therapeutic advances in gastrointestinal endoscopy
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mohamed ZaidDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8615-2456
Lauren WidmannDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Annie DaiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kevin SunDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jie ZhangDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jun ZhaoSheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mark W HurdSheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gauri R VaradhacharyDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Robert A WolffDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Anirban MaitraDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7923-9978
Matthew H G KatzDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joseph M HermanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Huamin WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael V KnoppDepartment of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Terence M WilliamsDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Priya BhosaleDepartment of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Eric P TammDepartment of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Eugene J KoayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor ImmunityR01CA248917 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G, KIM, HYUN · 2020 to 2024
$2.5M
Andrew Sabin Family Foundation FellowshipCenter of Advanced Biomedical Imaging CABIGE Healthcare GE HealthcareNCI NIH HHS Cancer Center Support (Core) Grant CA016672NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA248917NIH HHS U54CA210181-01, U54CA143837 and U01CA196403, 5U01CA200468, 1-U01-CA214263-01A1, 5P50CA221707-02, 5R01CA221971-03, R01-CA218004-01A1, 5R01CA203890-05Pancreatic Cancer Action Network 16-65-SINGPhilips Healthcare Philips HealthcareProject Purple Project PurpleSheikh Ahmed Center for Pancreatic Cancer Research Sheikh Ahmed Center for Pancreatic Cancer ResearchStand Up 2 Cancer SU2C-AACR-DT25-17University of Texas MD Anderson Cancer Center Moonshots program
6 · The paper itself

Abstract

Previously, we characterized qualitative imaging-based subtypes of pancreatic ductal adenocarcinoma (PDAC) on computed tomography (CT) scans. Conspicuous (high delta) PDAC tumors are more likely to have aggressive biology and poorer clinical outcomes compared to inconspicuous (low delta) tumors. Here, we developed a quantitative classification of this imaging-based subtype (quantitative delta; q-delta). Retrospectively, baseline pancreatic protocol CT scans of three cohorts (cohort#1 = 101, cohort#2 = 90 and cohort#3 = 16 [external validation]) of patients with PDAC were qualitatively classified into high and low delta. We used a voxel-based method to volumetrically quantify tumor enhancement while referencing normal-pancreatic-parenchyma and used machine learning-based analysis to build a predictive model. In addition, we quantified the stromal content using hematoxylin- and eosin-stained treatment-naïve PDAC sections. Analyses revealed that PDAC quantitative enhancement values are predictive of the qualitative delta scoring and were used to build a classification model (q-delta). Compared to high q-delta, low q-delta tumors were associated with improved outcomes, and the q-delta class was an independent prognostic factor for survival. In addition, low q-delta tumors had higher stromal content and lower cellularity compared to high q-delta tumors. Our results suggest that q-delta classification provides a clinically and biologically relevant tool that may be integrated into ongoing and future clinical trials.

Indexed as

computed tomographyimaging biomarkermachine learningpancreatic cancerradiomics

Identifiers

PMID33291471
PMCPMC7762105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.